Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
about
Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation.Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-AnalysisBleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.Ablation of atypical atrial flutters using ultra high density-activation sequence mapping.Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation.Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.Atrial fibrillation ablation using very short duration 50 W ablations and contact force sensing catheters.Factors impacting complication rates for catheter ablation of atrial fibrillation from 2003 to 2015.2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial designAntithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Soc
P2860
Q33872912-CE3916C4-F8E3-4446-8E09-32123FD481FEQ35631782-9E28C55E-B794-410E-8C0C-3E0D4CFD5F05Q35765335-937CE37C-64E1-4B68-B967-F3588FD6C2B7Q35868819-BC3492B2-DF45-457C-818E-FC1B4D2A3583Q37623666-2D8DCBDD-3292-48A7-9245-5E5879E448EAQ37666312-6A7A80B6-E51F-4CF6-9917-E49A0080BAEFQ38826010-328225B2-EFD6-4AD6-AEA6-6E348BBEDEBDQ39584450-68953656-811F-4706-93C8-BCC8DB046AEFQ40891224-A8647D98-8BD0-4EF0-A797-D7FE6D6D4282Q42172443-D7360313-C625-44BF-9CC8-C906002B6DAFQ42373398-BBD26DA7-F86F-462A-9476-E5C4123A363DQ45059153-8DC1B376-2680-4ACF-AE5D-DEB1C45355BCQ45069696-17B6AEE9-26DB-473F-B58A-76CD3A89347BQ46658026-86FF0964-3D76-4E24-8E8A-30830A47F9E5Q49824416-B8EEF33D-1300-4EB6-942C-0C9BB3AB0E71Q50906422-74FEFAAD-C996-4AA3-AB37-1EDE8B7A7465Q55263071-8F24E6FA-BBA7-419E-9980-689A6CCB2A31Q57626457-C847D456-8BB1-4970-B3E3-4E68ECDDA23A
P2860
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@ast
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@en
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@nl
type
label
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@ast
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@en
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@nl
prefLabel
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@ast
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@en
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@nl
P2093
P2860
P356
P1433
P1476
Peri-procedural interrupted or ...... , dabigatran, and rivaroxaban.
@en
P2093
Gregory Engel
Melissa H Kong
R Hardwin Mead
Rob A Patrawala
Roger A Winkle
P2860
P304
P356
10.1093/EUROPACE/EUU196
P577
2014-08-12T00:00:00Z